Filmed in September 2020 – Backed by extensive clinical evidence, the Decipher Prostate Genomic Classifier helps clinicians and their patients with prostate cancer make informed decisions for personalized treatment.
Join Ashley Ross, Ph.D., Urologist, Northwestern University, and Phuoc Tran, Ph.D., Radiation Oncologist, Johns Hopkins School of Medicine, as they discuss treatment decisions for intermediate risk disease.
Addressing the challenges of intermediate risk prostate cancer, which presents heterogeneous outcomes requiring personalized treatment approaches, they share their insights into how some patients need immediate intervention while others may be candidates for active surveillance.
Dr. Ross and Dr. Tran discuss clinical trials that have shaped the management of intermediate risk prostate cancer. Through a series of case studies of clinically favorable and unfavorable intermediate risk patients, they demonstrate the impact of Decipher Prostate on treatment decisions and its ability to enhance risk stratification of intermediate risk patients compared to clinical parameters alone.
Learn more about the power of genomics and how Decipher Prostate by Veracyte can improve personalized care for patients, help determine active surveillance eligibility for favorable intermediate risk patients, and guide ADT decisions for intermediate risk patients considering radiation therapy.
Working together with the cancer community, our mission is to advance prostate cancer care with exceptional genomic testing for personalized treatment planning.
Key topics
- 0:00 – Introduction
- 1:40 – Attendee Polling
- 2:40 – About Decipher
- 6:40 – Intermediate Risk Prostate Cancer Dilemma
- 12:00 – Treatment & Active Surveillance
- 14:00 – Decipher Prostate Data
- 16:30 – Use & Duration of ADT
- 20:00 – Registry Study
- 26:00 – Case Studies
- 53:00 – Key Points & Takeaways
Speakers
Ashley Ross, M.D., Ph.D.
Northwestern University
Phuoc Tran, M.D., Ph.D.
Johns Hopkins University
Tags
On Demand
Decipher Prostate